Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures

#1173

Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR

Aim(s): To verify the effects of Sunitinib on human Pheochromocytoma and Paraganglioma primary cultures

Materials and methods: 5 primary cultures (4 Pheochromocytoma and 1 Paraganglioma) were obtained from patients, followed in our centre, whose data about age, genetic alteration, histological features, and clinical events had been collected. Cell viability and apoptosis were measured by ATPlite and Caspase 3/7 assay.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bellio M, Gagliano T, Feo C, Balboni F, Gentilin E,

Keywords: Sunitinib, Pheochromocytoma, Paraganglioma ,